As a partner at Venrock, Bryan is involved with several companies across therapeutics, genomics, and HCIT, including 10X Genomics, Devoted Health, Element Biosciences, Encoded Therapeutics, Grand Rounds, and Lyra Health. Past investments include Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan). Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He received his B.A. from Dartmouth College.
Ed Mathers joined NEA as a Partner in August 2008 after spending 26 years working within the pharmaceutical/biotechnology industry in a variety of senior roles. Ed is focused on biotechnology and specialty pharmaceuticals investments, and is a director of Envisia Therapeutics, Liquidia Technologies, Lumos Pharmaceuticals, Mirna Therapeutics, Ra Pharmaceuticals, and Rhythm Pharmaceuticals. Previously, Ed was a director of Plexxikon prior to its sale to Daiichi Sankyo. Ed is also a member of the Biotechnology Industry Organization (BIO) board, Southeast Bio board, and the NC State Physical and Mathematical Sciences Foundation board.
Immediately prior to joining NEA, Ed served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc., and was a director of MedImmune, LLC. In this role, he was a member of the leadership team that executed the sale of the company to Astra Zeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he served as Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems (now Nektar). Previously, Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.
Former member of Eli Lilly’s executive committee leading Corporate Strategy and Business Development. Prior roles over a career spanning nearly three decades included president of US operations, various leadership positions in international regions and president of the women’s health franchise.
Eli Lilly & Co
James Niedel is a Managing Director and focuses on our biopharmaceuticals efforts. He joined the venture industry in 2002 and was one of the founders of New Leaf in 2005.Prior to those activities, Jim was Chief Science and Technology Officer for GlaxoSmithKline and from 1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research and Development, Information Technology and Product Strategy. From 1988 to 1995, he was VP Research and SVP R&D for the United Statess subsidiary of Glaxo. Before joining the pharmaceutical industry, Jim was Professor of Medicine and Chief of the division of Clinical Pharmacology at Duke Medical School, where he had completed an Internal Medicine residency and a Hematology-Oncology fellowship. He received M.D. and Ph.D. (Biochemistry) degrees from the University of Miami, was selected a Searle Scholar, and is a Fellow of the Royal College of Physicians (London).</br></br>Board Seats: </br>Intarcia Therapeutics,Tioga Pharmaceuticals,Tolerx</br></br>Contact Information:</br>jim@nlvpartners.
Achaogen, Adavium Medical, Ariosa Diagnostics, Castlight Health, CodeRyte, CoolSculpting, Dare Bioscience, Fate Therapeutics, First Genetic Trust, Ikaria, Ironwood Pharmaceuticals, Kyruus, Powervision, Ren Pharmaceuticals, Satiety, Sirna Therapeutics, Surface Logix, and Vitae Pharmaceuticals
Alder BioPharmaceuticals, Alexza Pharmaceuticals, Calithera Biosciences, Ilypsa, Karyopharm Therapeutics, NeurAxon, OncoMed Pharmaceuticals, PTC Therapeutics, and Relypsa
Liquidia Technologies, Mirna Therapeutics, Rhythm Pharmaceuticals, and Satori Pharmaceuticals
Allena Pharmaceuticals, AMAG Pharmaceuticals, Collegium Pharmaceutical, Horizon Therapeutics, Intercept Pharmaceuticals, LivaNova, Sorin Group, and Vitae Pharmaceuticals
Chimerix, and Pearl Therapeutics